John G. Singer 4/24/25 John G. Singer 4/24/25 The Invisible Hand Slaps Hard Read More John G. Singer 4/23/25 John G. Singer 4/23/25 Technology is More Irrelevant Than Ever Read More John G. Singer 4/17/25 John G. Singer 4/17/25 The Innovation Fallacy in Healthcare Read More John G. Singer 4/14/25 John G. Singer 4/14/25 The Delicate Art of 'Strategic Fit' Read More John G. Singer 4/11/25 John G. Singer 4/11/25 Killer Mayhem Read More John G. Singer 4/8/25 John G. Singer 4/8/25 Should Sanofi and Pepsi Combine as a New ‘Market Set’? Read More John G. Singer 4/3/25 John G. Singer 4/3/25 LillyDirect vs. NovoCare vs. PfizerForAll: May the Best Ecosystem Win Read More John G. Singer 3/27/25 John G. Singer 3/27/25 Modern Strategy Moves Like a Crab Read More John G. Singer 3/25/25 John G. Singer 3/25/25 Should PhRMA Acquire 23andMe? Read More John G. Singer 3/20/25 John G. Singer 3/20/25 Is Africa a Better 'Vaccine Market' Than the United States? Read More John G. Singer 3/17/25 John G. Singer 3/17/25 Can Novartis Save the NHS? Read More John G. Singer 3/12/25 John G. Singer 3/12/25 What’s the Business Value of the VA to Eli Lilly? Read More John G. Singer 3/5/25 John G. Singer 3/5/25 A Slight Case of Overbombing Read More John G. Singer 3/3/25 John G. Singer 3/3/25 How to Make $164 Billion from “Malaria” — A Modern Strategy Story Read More John G. Singer 2/27/25 John G. Singer 2/27/25 PhRMA Hosts Tiki Barber, Talks Obsolete Game Plan Read More John G. Singer 2/20/25 John G. Singer 2/20/25 Is HIV Prevention and Treatment "Gender-Affirming Care"? Read More John G. Singer 2/17/25 John G. Singer 2/17/25 The Massive Grapple Ahead for Pharma Read More John G. Singer 2/13/25 John G. Singer 2/13/25 How to Sell AI in the Kingdom of the Bored Read More John G. Singer 2/6/25 John G. Singer 2/6/25 Whatever Happened to Eisai’s “Dementia Ecosystem”? Read More John G. Singer 1/31/25 John G. Singer 1/31/25 Should Eli Lilly Acquire Walgreens? Should Novo Nordisk? Read More Newer Posts Older Posts
John G. Singer 4/8/25 John G. Singer 4/8/25 Should Sanofi and Pepsi Combine as a New ‘Market Set’? Read More
John G. Singer 4/3/25 John G. Singer 4/3/25 LillyDirect vs. NovoCare vs. PfizerForAll: May the Best Ecosystem Win Read More
John G. Singer 3/20/25 John G. Singer 3/20/25 Is Africa a Better 'Vaccine Market' Than the United States? Read More
John G. Singer 3/12/25 John G. Singer 3/12/25 What’s the Business Value of the VA to Eli Lilly? Read More
John G. Singer 3/3/25 John G. Singer 3/3/25 How to Make $164 Billion from “Malaria” — A Modern Strategy Story Read More
John G. Singer 2/27/25 John G. Singer 2/27/25 PhRMA Hosts Tiki Barber, Talks Obsolete Game Plan Read More
John G. Singer 2/20/25 John G. Singer 2/20/25 Is HIV Prevention and Treatment "Gender-Affirming Care"? Read More
John G. Singer 2/6/25 John G. Singer 2/6/25 Whatever Happened to Eisai’s “Dementia Ecosystem”? Read More
John G. Singer 1/31/25 John G. Singer 1/31/25 Should Eli Lilly Acquire Walgreens? Should Novo Nordisk? Read More
